Profile data is unavailable for this security.
About the company
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
- Revenue in USD (TTM)25.37k
- Net income in USD-12.62m
- Incorporated2002
- Employees16.00
- LocationABVC Biopharma Inc44370 Old Warm Springs BlvdFREMONT 94538-6148United StatesUSA
- Phone+1 (510) 668-0881
- Websitehttps://abvcpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CV Sciences Inc | 15.86m | -3.23m | 9.47m | 42.00 | -- | 4.01 | -- | 0.597 | -0.0207 | -0.0207 | 0.1012 | 0.0145 | 1.59 | 1.42 | 27.25 | 377,571.40 | -32.43 | -43.42 | -83.71 | -77.75 | 45.13 | 51.81 | -20.38 | -45.68 | 0.2677 | -13.32 | 0.0472 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Oragenics Inc | 20.63k | -20.26m | 9.50m | 5.00 | -- | 9.20 | -- | 460.45 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| BioCardia Inc | 468.00k | -10.34m | 9.56m | 16.00 | -- | -- | -- | 20.42 | -0.4692 | -0.4692 | 0.0209 | -0.0848 | 0.0954 | -- | 4.44 | 29,250.00 | -210.81 | -107.34 | -1,190.90 | -154.17 | -- | -- | -2,208.76 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Enzon Pharmaceuticals Inc | 0.00 | 221.00k | 9.73m | 0.00 | 44.01 | 2.95 | -- | -- | 0.003 | 0.003 | 0.00 | 0.624 | 0.00 | -- | -- | -- | 3.21 | -0.8654 | 3.24 | -0.8851 | -- | -- | -- | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -16.31m | 9.87m | 5.00 | -- | 2.22 | -- | -- | -0.5804 | -0.5804 | 0.00 | 0.1197 | 0.00 | -- | -- | 0.00 | -212.70 | -36.90 | -378.58 | -37.81 | -- | -- | -- | -- | -- | -- | 0.349 | -- | -- | -- | 43.40 | -- | -- | -- |
| Universe Pharmaceuticals Inc | 32.31m | -6.16m | 10.03m | 225.00 | -- | 0.2522 | -- | 0.3103 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| ABVC Biopharma Inc | 25.37k | -12.62m | 10.04m | 16.00 | -- | 1.27 | -- | 395.70 | -2.37 | -2.37 | 0.0043 | 0.7284 | 0.002 | -- | 0.0673 | 1,585.63 | -103.15 | -103.38 | -189.31 | -231.54 | -854.20 | 76.25 | -51,218.29 | -2,019.89 | -- | -3.19 | 0.1853 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -20.94m | 10.13m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| Eterna Therapeutics Inc | 115.00k | -22.92m | 10.33m | 8.00 | -- | -- | -- | 89.86 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 10.39m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| 22nd Century Group Inc | 29.75m | -62.89m | 10.53m | 64.00 | -- | -- | -- | 0.354 | -40.02 | -97.93 | 17.94 | -3.23 | 0.40 | 5.90 | 5.47 | 464,796.90 | -66.29 | -46.78 | -92.49 | -54.18 | -33.09 | -2.11 | -165.75 | -107.95 | 0.4284 | -3.67 | 4.76 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 10.55m | 4.00 | -- | -- | -- | 14,065.96 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -26.82m | 10.59m | 18.00 | -- | 0.4904 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Shineco Inc | 5.62m | -14.34m | 10.64m | 87.00 | -- | 0.2955 | -- | 1.89 | -3.98 | -2.32 | 1.36 | 5.58 | 0.0664 | 0.48 | 1.45 | 64,633.68 | -19.79 | -12.77 | -38.28 | -16.84 | 12.77 | 25.88 | -298.09 | -102.06 | 0.4842 | -8.14 | 0.3908 | -- | -- | -58.35 | -33.86 | -- | -- | -- |
Data as of May 28 2024. Currency figures normalised to ABVC Biopharma Inc's reporting currency: US Dollar USD
2.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Chase Investment Counsel Corp.as of 31 Mar 2024 | 178.38k | 1.69% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 46.95k | 0.45% |
| Geode Capital Management LLCas of 31 Mar 2024 | 22.00k | 0.21% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 4.44k | 0.04% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.52k | 0.02% |
| Spotlight Asset Group, Inc.as of 31 Mar 2024 | 100.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 48.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 37.00 | 0.00% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
